Welcome to PsychiatryAI.com: [PubMed] - Psychiatry AI Latest

Long-Term Cardiovascular Risks of Psychostimulant Drugs for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)

Evidence

J Am Coll Cardiol. 2024 May 14;83(19):1883-1885. doi: 10.1016/j.jacc.2024.03.409.

NO ABSTRACT

PMID:38719368 | DOI:10.1016/j.jacc.2024.03.409

Document this CPD Copy URL Button

Google

Google Keep Add to Google Keep

LinkedIn Share Share on Linkedin Share on Linkedin

Estimated reading time: 1 minute(s)

Latest: Psychiatryai.com #RAISR4D

Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️

Real-Time Evidence Search [Psychiatry]

AI Research [Andisearch.com]

Long-Term Cardiovascular Risks of Psychostimulant Drugs for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)

Copy WordPress Title

🌐 90 Days

Evidence Blueprint

Long-Term Cardiovascular Risks of Psychostimulant Drugs for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)

QR Code

☊ AI-Driven Related Evidence Nodes

(recent articles with at least 5 words in title)

More Evidence

Long-Term Cardiovascular Risks of Psychostimulant Drugs for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)

🌐 365 Days

Floating Tab
close chatgpt icon
ChatGPT

Enter your request.